EUROPCAR/TAXEO
22.6.2016 17:41:21 CEST | Business Wire | Press release
Regulatory News:
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160622006054/en/
Whether renting a car or booking a hotel, travelling for business in Europe incurs VAT costs. Europcar (Paris:EUCAR) he leading car rental provider in Europe and a major mobility player, and Taxeo, the leading provider of paperless VAT refund services, have entered into a partnership so their mutual clients are able to reclaim VAT quickly and easily according to local legislation.
The unique innovation developed by Taxeo is to receive electronic invoice data from Europcar and create tax-compliant electronic invoices that are used for VAT recovery.
Thanks to this partnership, Europcar Corporate customers are set to make significant savings.
Jean Cazes, CEO of Taxeo, called it a “milestone” in VAT recovery for business travel expenses. “This means that we are able to reduce car hire costs for our mutual clients by up to 15%. Our solution is very simple for companies and travellers to use. Moreover, it brings the additional benefit of tax-compliant e-invoices and structured data for expense management ” Cazes added.
Marcus Bernhardt, Chief Commercial Officer of the Europcar Group, also sees the partnership with the French company as a “wonderful opportunity” for the business: “This meets the price-sensitivity of our corporate clients and boosts our competitiveness and differentiation without impacting our revenues and commitment to service .”
Every year companies lose out on €5 billion VAT incurred on international travel. Today’s manual paper-based VAT recovery process, especially for travel expenses like hotel, car rental, conferences, etc., is complex, expensive, and inefficient, due mainly to non-compliant or lost invoices. The Taxeo solution addresses these issues. What’s more, a majority of small and medium-sized enterprises (SMEs) are often unaware that VAT can be refunded for business trips or how to apply for refund.
About Europcar Group:
Europcar shares (EUCAR) are
listed on the Euronext Paris stock exchange. Europcar is the European
leader in vehicle rental service and is also a major player in mobility
markets. Active in more than 140 countries, Europcar serves customers
through an extensive vehicle rental network comprised of its
wholly-owned subsidiaries as well as sites operated by franchisees and
partners. In addition to the Europcar® brand, the company offers
low-cost vehicle rentals under the InterRent® brand. A commitment to
customer satisfaction drives the company and its 6,000 people forward
and provides the impetus for continuous development of new services.
The Europcar Lab was created to respond to tomorrow’s mobility
challenges through innovation and strategic investments, such as Ubeeqo
and E-Car Club.
About Taxeo:
Taxeo is a FinTech startup, which has
developed the first paperless and fully automated VAT reclaim solution
for international European business travel.
Taxeo helps many
European and US based companies to recover VAT on travel related
expenses and supplier invoices.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622006054/en/
Contact:
Media Contacts
EUROPCAR
Europcar
Press Office,
Tel: + 33 1 30 44 98 82
europcarpressoffice@europcar.com
or
Havas
Paris
Tel. +33 1 58 47 95 39
jean-baptiste.froville@havasww.com
or
Taxeo
Nils
Kernchen / Ama Lorenz
Tel: +33 1 43 87 71 14
n.kernchen@taxeo.com
press@taxeo.com
www.taxeo.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom